A REVIEW OF LINSITINIB SIDE EFFECTS

The LIDS trial satisfied its Key endpoint with statistical importance for the 150mg BID dose. Linsitinib On this trial validated the protection profile found while in the prior oncology research and importantly demonstrated a favorable security profile on essential adverse situations (AEs) of interest for the IGF-1R goal including hearing impairmen